Esperion Therapeutics Inc Annual Shareholders Meeting Transcript
Good morning, and welcome to the 2021 Esperion Annual Meeting of Stockholders. I'm Kaitlyn Brosco, Senior Manager, Corporate Communications and Investor Relations. I would now like to turn the meeting over to Sheldon Koenig, President and Chief Executive Officer of Esperion to lead today's events. Mr. Koenig, please go ahead.
Thank you, Kate, and good morning, everyone. I'd like to welcome you to the 8th Annual Esperion's Stockholders Meeting, which is now called to order. We are excited to be hosting our sixth annual virtual meeting of stockholders, and my first as President and CEO of Esperion. I would just like to say I am honored to be here and confident in the future of this organization. I am incredibly optimistic for the future of our commercial medicines, NEXLETOL and NEXLIZET, and their ability to address a large unmet need within the cardiovascular and LDL-cholesterol lowering space. Even more, I am optimistic for the long-term potential of Esperion as a company,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |